Antipsychotic drugs associated with high blood sugar in older adults with diabetes

Jul 27, 2009

Older patients with diabetes who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a report in the July 27 issue of Archives of Internal Medicine.

An increasing number of are being prescribed antipsychotic drugs for dementia and other conditions, according to background information in the article. However, these medications may be associated with adverse effects—including Parkinson's disease symptoms, stroke and diabetes—in the older population. "The risk of diabetes may be partly related to chronic effects of the weight gain associated with antipsychotic agents," the authors write. "However, case reports of acute hyperglycemia after the initiation of therapy with these drugs suggest that they may also be associated with acute glycemic [] changes."

Lorraine L. Lipscombe, M.D., M.Sc., of the Institute for Clinical Evaluative Sciences, University of Toronto and Women's College Research Institute at Women's College Hospital, Toronto, Ontario, Canada, and colleagues studied 13,817 individuals age 66 and older (average age 78) with diabetes who began treatment with antipsychotics between April 1, 2002, and March 31, 2006. Each patient who was hospitalized for hyperglycemia during the observation period—through March 31, 2007, an average of two years of follow-up—was considered a case and was matched with up to 10 control patients who were the same age and sex but were not hospitalized over the same time period. The researchers then compared the likelihood of hyperglycemia among those who were currently taking antipsychotic medications to those who had discontinued antipsychotic medications for more than 180 days.

Of the total group of 13,817 patients, 1,515 (11 percent) were hospitalized for hyperglycemia. Those who were currently taking antipsychotic drugs had a higher risk of hospitalization than those who had stopped the medications more than 180 days ago. The risk was highest among those who were just starting antipsychotic drug treatment.

"Our study indicates that the initiation of antipsychotic therapy represents a critical period during which seniors with diabetes are particularly vulnerable to metabolic decompensation [failure of the metabolic system to function adequately]," the authors write. "The new use of both atypical [newer] and typical antipsychotic drugs was associated with a significant increase in hospitalizations for hyperglycemia, which appeared independent of baseline diabetes treatment and was strikingly high during the initial period of antipsychotic therapy."

Some previous evidence suggests that the neurotransmitter dopamine has a role in regulating blood glucose levels; first-time antipsychotic users may experience an acute disruption in this system, leading to hyperglycemic episodes, the authors note. However, further studies are needed to confirm a causal effect and identify the mechanisms involved. "In the meantime, other options to manage behavioral symptoms of should be considered among older persons with diabetes," they conclude. "Patients and their families should be alerted to observe for signs of glycemic decompensation when treatment with an antipsychotic agent is initiated, and enhanced glucose monitoring is recommended for all patients for whom an antipsychotic drug is prescribed, particularly after treatment initiation."

More information: Arch Intern Med. 2009;169[14]:1282-1289.

Source: JAMA and Archives Journals (news : web)

Explore further: Merck ends development of Parkinson's disease drug

add to favorites email to friend print save as pdf

Related Stories

Report says older drugs just as good

Oct 03, 2006

A British study says schizophrenia patients do as well, if not better, on older psychiatric drugs as on newer and far costlier ones.

Recommended for you

J&J expects 10-plus new drug applications by 2017

6 hours ago

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Glaxo, US partnering to develop new antibiotics

May 22, 2013

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

User comments : 0

More news stories

Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Ferrets, pigs susceptible to H7N9 avian influenza virus

Chinese and U.S. scientists have used virus isolated from a person who died from H7N9 avian influenza infection to determine whether the virus could infect and be transmitted between ferrets. Ferrets are often used as a mammalian ...

A quantum simulator for magnetic materials

Physicists understand perfectly well why a fridge magnet sticks to certain metallic surfaces. But there are more exotic forms of magnetism whose properties remain unclear, despite decades of intense research. ...